Eisai's breast cancer drug extends lives: Study

Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said on Sunday.

Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said on Sunday.

HT Image

The results of the Phase III trial, presented to a meeting of the American Society of Clinical Oncology in Chicago, should change practice, conference organizers told reporters.